Transformative Research in Diabetic Nephropathy (TRIDENT)
Diabetes Mellitus - Type 1 | Diabetes Mellitus - Type 2
What is the purpose of this trial?
This is a prospective, observational, cohort study of patients with a clinical diagnosis of diabetes who are undergoing clinically indicated kidney biopsy. The intent is to collect, process, and study kidney tissue and to harvest blood, urine and genetic materials to elucidate molecular pathways and link them to biomarkers that characterize those patients have a rapid decline in kidney function (> 5 mL/min/1.73m2/year) from those with lesser degrees of kidney function change over the period of observation. High through-put genomic analysis associated with genetic and biomarker testing will serve to identify key potential therapeutic targets for DKD by comparing patients with rapid and slow progression patterns. Each participating clinical site will search for, consent, harvest the biopsy sample, and enroll the participants as required for the TRIDENT protocol.
- Ages18 years - 100 years
- Trial withUniversity of Pennsylvania
- Start Date05/16/2018
- End Date11/29/2019
- Last Updated05/18/2018
- Study HIC#2000022587